Cardiologist William Hiatt (University of Colorado School of Medicine) has a problem with the Food & Drug Administration’s proposal to require cardiovascular outcomes studies for all weight loss drugs, even in the absence of a clear signal of CV risk.
“If you want to impose this requirement on a drug with no signals, I think you ought to impose it on all drugs designed for symptomatic indications,” Hiatt declared near the end of the Endocrinologic & Metabolic Drugs Advisory
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?